Consensus $4.83. Lowers FY26 revenue view to up 1%-4% from up 3%-6%.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics reports Q2 adjusted EPS $1.27, consensus $1.11
- Haemonetics (HAE) Q2 Earnings Cheat Sheet
- Haemonetics: Strategic Adjustments and Growth Potential Justify Buy Rating Despite Revenue Challenges
- Haemonetics price target lowered to $64 from $78 at Citi
- Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance